Get started

Financials · RGNX

REGENXBIO Inc. (RGNX) financials

For the twelve months ended Sep 30, 2026, REGENXBIO Inc. reported $153.91M of revenue and -$175.23M of net income.

Revenue, TTM
$153.91M
Revenue growth, YoY
-4.6%
Net income, TTM
-$175.23M
Net margin
-113.9%
Free cash flow, TTM
-$154.80M
EPS, diluted, TTM
-$3.21
Cash
$95.80M
P/S
3.64
Market cap
$560.1M
Annual revenue$170.44M
FY2016FY2025
Annual net income-$193.88M
FY2016FY2025
Annual free cash flow-$126.38M
FY2016FY2025

RGNX revenue and earnings growth

RGNX revenueQ3 2026$9.16M

Quarter YoY
-69.2%
QoQ
-91.5%
FY YoY
+104.5%
5Y CAGR
+2.0%
10Y CAGR
+36.5%

RGNX revenue was $9.16M in fiscal Q3 2026 (ended Sep 30, 2026), down 69.2% from a year earlier and down 91.5% from the prior quarter. For the full fiscal 2025 it was $170.44M, up 104.5% from fiscal 2024. Compound annual growth was +2.0% over 5 years and +36.5% over 10 years. It rose in 5 of the last 10 fiscal years.

RGNX net incomeQ3 2026-$40.74M

RGNX net income was -$40.74M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$61.94M a year earlier. For the full fiscal 2025 it was -$193.88M, compared with -$227.10M in fiscal 2024.

RGNX EPSQ3 2026-$0.62

RGNX diluted EPS was -$0.62 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.20 a year earlier. For the full fiscal 2025 it was -$3.76, compared with -$4.59 in fiscal 2024.

RGNX free cash flowQ3 2026$38.41M

RGNX free cash flow was $38.41M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$56.45M a year earlier. For the full fiscal 2025 it was -$126.38M, compared with -$175.56M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$170.44M$83.33M$90.24M$112.72M$470.35M$154.57M$35.23M$218.50M$10.39M$4.59M
Cost of revenue-$33.57M$37.21M$54.55M$51.83M$35.71M$8.24M$9.64M$1.71M$98.0K
Gross profit-$49.76M$53.03M$58.18M$418.51M$118.85M$26.99M$208.87M$8.68M$4.49M
Research and development$228.30M$208.52M$232.27M$242.45M$181.44M$166.29M$124.19M$83.87M$57.22M$45.48M
Selling, general and admin$82.86M$76.62M$88.49M$85.28M$79.33M$63.82M$51.81M$36.85M$27.23M$23.59M
Operating income-$161.20M-$233.35M-$268.13M-$262.88M$159.98M-$119.23M-$149.00M$88.10M-$75.89M-$65.34M
Interest expense$45.01M$12.66M$6.86M$23.25M$26.28M$771.0K----
Pre-tax income-$193.88M-$227.10M-$263.65M-$280.40M$141.25M-$106.01M-$97.49M$104.12M-$73.17M-$63.40M
Income tax$0$0-$152.0K-$84.0K$13.41M$5.24M-$2.75M$4.18M$0-$435.0K
Net income-$193.88M-$227.10M-$263.49M-$280.32M$127.84M-$111.25M-$94.73M$99.94M-$73.17M-$62.97M
EPS, basic-$3.76-$4.59-$6.02-$6.50$3.01-$2.98-$2.58$2.99-$2.45-$2.38
EPS, diluted-$3.76-$4.59-$6.02-$6.50$2.91-$2.98-$2.58$2.73-$2.45-$2.38
Diluted shares51.6M49.5M43.7M43.2M43.9M37.3M36.7M36.6M29.9M26.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$34.47M$57.53M$34.52M$96.95M$345.21M$338.43M$69.51M$75.56M$46.66M$24.84M
Short-term investments$195.60M$177.16M$240.74M$267.69M$112.23M$137.31M$226.70M$244.20M$114.12M$64.71M
Receivables$26.38M$20.47M$24.79M$28.08M$32.44M$43.00M$38.15M---
Current assets$281.28M$278.00M$334.97M$415.98M$518.83M$531.20M$345.03M$337.91M$168.00M$93.37M
Total assets$453.03M$465.99M$573.97M$833.27M$1.11B$708.16M$497.91M$543.81M$198.68M$172.73M
Current liabilities$118.09M$103.19M$130.27M$130.43M$130.47M$81.45M$33.68M$22.18M$14.44M$9.67M
Total liabilities$350.30M$206.34M$262.23M$317.07M$349.61M$330.41M$47.71M$34.97M$15.65M$10.99M
Shareholders' equity$102.73M$259.65M$311.74M$516.20M$764.30M$377.75M$450.20M$508.85M$183.03M$161.74M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$123.96M-$173.13M-$218.41M-$207.49M$218.88M-$54.06M-$107.70M$104.65M-$57.99M-$48.56M
Capital expenditures$2.41M$2.44M$9.96M$30.72M$84.17M$26.87M$11.72M$13.28M$7.16M$8.15M
Free cash flow-$126.38M-$175.56M-$228.37M-$238.21M$134.70M-$80.93M-$119.42M$91.37M-$65.15M-$56.71M
Investing cash flow-$15.87M$103.45M$190.94M-$11.93M-$406.64M$122.76M$93.56M-$279.36M-$4.79M$19.39M
Financing cash flow$116.77M$92.68M-$34.97M-$28.84M$195.25M$200.21M$8.38M$204.44M$84.60M$119.0K
Stock-based compensation$34.56M$38.46M$40.27M$40.79M$38.81M$31.95M$26.85M$16.64M$10.61M$7.03M
Depreciation and amortization$15.62M$16.21M$17.32M$12.91M$9.56M$8.41M$7.15M$3.98M$2.69M$544.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY104.5%-7.7%-19.9%-76.0%204.3%338.7%-83.9%2002.4%126.5%-39.5%
Gross margin-59.7%58.8%51.6%89.0%76.9%76.6%95.6%83.6%97.9%
Operating margin-94.6%-280.0%-297.1%-233.2%34.0%-77.1%-422.9%40.3%-730.2%-1423.8%
Net margin-113.8%-272.5%-292.0%-248.7%27.2%-72.0%-268.9%45.7%-704.0%-1372.1%
Free cash flow margin-74.1%-210.7%-253.1%-211.3%28.6%-52.4%-339.0%41.8%-626.9%-1235.7%
Return on equity-188.7%-87.5%-84.5%-54.3%16.7%-29.5%-21.0%19.6%-40.0%-38.9%
Return on assets-42.8%-48.7%-45.9%-33.6%11.5%-15.7%-19.0%18.4%-36.8%-36.5%
Current ratio2.382.692.573.193.986.5210.2515.2411.649.66

Source: XBRL data REGENXBIO Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RGNX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RGNX$153.91M-4.6%-$175.23M-113.9%$560.1M
QURE$20.17M+28.0%-$232.90M-1154.8%$1.72B
MGTX$397.50M+948.3%$78.98M19.9%$929.7M
RCKT$0--$17.25M-$272.2M
VYGR$25.11M-19.8%-$104.53M-416.3%$109.2M

RGNX FAQ

8 questions
  • What is RGNX revenue?
    REGENXBIO Inc. (RGNX) reported $153.91M of revenue for the twelve months ended Sep 30, 2026. That is down 4.6% from the year before. Revenue for fiscal 2025 was $170.44M.
  • Is RGNX profitable?
    No. REGENXBIO Inc. reported a net loss of $175.23M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RGNX have?
    REGENXBIO Inc. reported $95.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is RGNX revenue growing?
    REGENXBIO Inc.'s revenue changed +104.5% in fiscal 2025, to $170.44M. Its compound annual growth rate was +2.0% over 5 years and +36.5% over 10 years.
  • What is RGNX free cash flow?
    REGENXBIO Inc. generated -$154.80M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$152.10M less capital expenditures.
  • What is RGNX earnings per share?
    Diluted earnings per share were -$3.21 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RGNX last report financial results?
    The latest statements here come from REGENXBIO Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this RGNX financial data come from?
    Quantisnow builds these statements from the structured XBRL data REGENXBIO Inc. files with the SEC. It is provided for information only and is not investment advice.